Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel (WP) or eribulin (E) followed by doxorubicin and cyclophosphamide (AC) in women with locally advanced HER2-negative breast cancer (LABC): NSABP FB-9.
Jame Abraham
No relevant relationships to disclose
Andre Robidoux
Honoraria - Eisai Canada; Novartis Canada; Roche Canada
Antoinette R. Tan
Research Funding - Eisai
Marc E. Buyse
Employment or Leadership Position - IDDI
Stock Ownership - IDDI
Norman Wolmark
No relevant relationships to disclose
Samuel A. Jacobs
No relevant relationships to disclose